Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

17.4K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
17.4K
Defense Against Bacterial Pathogens01:31

Defense Against Bacterial Pathogens

3.2K
The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Source-sink dynamics of WADA-prohibited compounds in coastal urban aquatic environments: From WWTP to bay.

Journal of environmental management·2026
Same author

Environmental and microbial regulation of multi-temporal scale methane flux dynamics in a shallow karst lake.

Water research·2026
Same author

Multi-species and life-stage patterns of cyanobacterial VOC emissions: Abiotic stress responses and photochemical impacts.

Environmental research·2025
Same author

<sup>157</sup>Gd-DHK: enhancing targeted gadolinium neutron capture for pancreatic adenocarcinoma.

Journal of cancer research and clinical oncology·2025
Same author

Berberine derivative C51 modulates cGAS-STING-TIM-3 axis to reverse immune evasion and inhibit lung cancer growth.

Cellular signalling·2025
Same author

Emission characteristics and formation mechanisms of toluene during anaerobic degradation of cyanobacteria.

Journal of hazardous materials·2025

Related Experiment Video

Updated: Feb 28, 2026

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

15.3K

Systemic Immunity Triggered by Boron Neutron Capture Therapy via Manganese-Borate Complex.

Chang Chen1, Chao Wang2,3, Lin Zhang4

  • 1Institute of Energy, Hefei Comprehensive National Science Center (Anhui Energy Laboratory), Hefei, Anhui, 230031, China.

Materials Today. Bio
|February 26, 2026
PubMed
Summary

A novel albumin-based boron neutron capture therapy (BNCT) agent, Albumin@MnB, enhances antitumor immunity and suppresses tumor growth more effectively than traditional agents. This breakthrough offers a new path for boron neutron capture immunotherapy (BNCI).

Keywords:
AlbuminBiomineralizedBoron neutron capture therapyEnergy Starvation.ImmunotherapyRadiotherapy

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.3K
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

11.1K

Related Experiment Videos

Last Updated: Feb 28, 2026

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

15.3K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.3K
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

11.1K

Area of Science:

  • Biomedical Engineering
  • Immunotherapy
  • Radiochemistry

Background:

  • Conventional radiotherapy can impair antitumor immunity due to collateral damage to immune cells.
  • Boron neutron capture therapy (BNCT) offers tumor-selective cell killing via 10B (n, α) 7Li reactions, but current agents like boronophenylalanine (BPA) require high doses and show limited immune engagement.
  • There is a need for advanced BNCT agents that can enhance immunotherapeutic effects and overcome the limitations of existing treatments.

Purpose of the Study:

  • To develop and evaluate a novel biomineralized albumin-based BNCT agent (Albumin@MnB) for enhanced tumor suppression and immunotherapeutic activation.
  • To compare the efficacy of Albumin@MnB with the clinical agent BPA at reduced boron doses.
  • To investigate the potential of Albumin@MnB to synergize with other immunotherapies, such as adoptive T cell transfer and immune checkpoint inhibitors.

Main Methods:

  • Synthesis of Albumin@MnB using clinically accessible borax, manganese, and albumin.
  • Evaluation of tumor suppression efficacy in preclinical models, comparing Albumin@MnB with BPA.
  • Assessment of intratumoral immune cell infiltration and distant tumor growth inhibition.
  • Combination studies with adoptive T cell immunotherapy and immune checkpoint inhibitors.

Main Results:

  • Albumin@MnB demonstrated potent tumor suppression at reduced boron doses, outperforming BPA.
  • The novel agent significantly enhanced intratumoral immune cell infiltration.
  • Albumin@MnB suppressed distant tumor growth, indicating systemic effects.
  • Synergistic effects were observed when Albumin@MnB was combined with adoptive T cell immunotherapy and immune checkpoint inhibitors.

Conclusions:

  • Albumin@MnB represents a promising advancement in BNCT, offering superior efficacy and reduced boron dosage compared to BPA.
  • This agent activates antitumor immunity by integrating targeted radiolysis with metabolic reprogramming and immune activation.
  • Albumin@MnB establishes boron neutron capture immunotherapy (BNCI) as a multimodal therapeutic strategy, bridging targeted cell killing with systemic immune responses.